An independent panel of advisers to the Food and Drug Administration overwhelmingly recommended that the agency authorize Moderna’s Covid-19 vaccine for emergency use on Thursday, bringing the United States one step closer to adding a second vaccine to its toolkit in fighting the pandemic.Members of the Vaccines and Related Biological Products Advisory Committee voted 20 to 0 in favor of recommending authorization, with one abstention.Full coverage of the coronavirus outbreakThe FDA is expected to agree with the committee’s recommendation, and an emergency use authorization could come as soon as Thursday evening or Friday.Acting chair of the advisory group, Dr. Arnold Monto of the University of Michigan School of Public Health, called Moderna’s work a “remarkable achievement.””Based on the totality of scientific evidence available, I strongly support it because the benefits outweigh its risks,” said Dr. Melinda Wharton, director of the Immunization Services Division in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention.Dr. Michael Kurilla, an infectious disease expert with the National Institutes of Health, was the sole member to abstain from the vote. He said he felt the question on which the committee voted, “Based on the totality of scientific evidence available,

Continue To Full Article